Search
Partnering in RBB HP OCTOBER CORP.pdf
Partnering in Biotherapeutics HP OCTOBER 2024 CORP_1.pdf
Partnering in Technologies HP OCTOBER 2024 CORP.pdf
Partnering in Mental Health Disorders HP OCTOBER 2024 CORP.pdf
Partnering in Cardio-Renal-Metabolic HP OCTOBER 2024 CORP.pdf
Partnering in Immunology & Resp HP OCTOBER 2024 CORP.pdf
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.
cat feline diabetes medication treatment eu approval
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Cristian Torreblanca
Cristian Torreblanca Estrada is a Corporate Global Facilities and Engineering Senior Manager Controller in Germany – with plans for growth across the global business.
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Cancer
Cancer
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality